

## **MicroRNA Biomarkers and Platelet Reactivity – the “Clot” Thickens**

Nicholas Sunderland<sup>1</sup>, Philipp Skroblin<sup>1</sup>, Temo Barwari<sup>1</sup>, Rachael P. Huntley<sup>2</sup>,  
Ruifang Lu<sup>1</sup>, Abhishek Joshi<sup>1</sup>, Ruth C. Lovering<sup>2</sup>, Manuel Mayr<sup>1</sup>

<sup>1</sup> King's British Heart Foundation Centre, King's College London, United Kingdom

<sup>2</sup> Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, United Kingdom

**Short Title:** Non-coding RNAs in platelets

**Corresponding author:**

Prof. Manuel Mayr, King's British Heart Foundation Centre, King's College London, 125 Coldharbour Ln, London SE5 9NU, United Kingdom, Fax number: +44 (0)20 7848 5132, Tel number: +44 (0)20 7848 5132; email: [manuel.mayr@kcl.ac.uk](mailto:manuel.mayr@kcl.ac.uk)

**Abstract**

Over the last few years, several groups have evaluated the potential of microRNAs (miRNAs) as biomarkers for cardiometabolic disease. In this review we discuss the emerging literature on the role of miRNAs and other small non-coding RNAs in platelets and the circulation, and the potential use of miRNAs as biomarkers for platelet activation. Platelets are a major source of miRNAs, YRNAs and circular RNAs. By harnessing multi-omics approaches, we may gain valuable insights into their potential function. Since not all miRNAs are detectable in the circulation, we also created a Gene Ontology (GO) annotation for circulating miRNAs using the GO term "extracellular space" as part of blood plasma. Finally, we share key insights for measuring circulating miRNAs. We propose ways to standardize miRNA measurements, in particular by using platelet-poor plasma to avoid confounding caused by residual platelets in plasma, or by adding RNase inhibitors to serum to reduce degradation during sample storage. This should enhance comparability of miRNA measurements across different cohorts. We provide recommendations for future miRNA biomarker studies, emphasizing the need for accurate interpretation within a biological and methodological context.

**Keywords**

biomarker; non-coding RNA; platelet; platelet inhibitor; acute coronary syndrome

**Non-Standard Abbreviations and Acronyms**

circRNAs	-	circular RNAs
Ct	-	cycle threshold
GO	-	gene ontology
lncRNAs	-	long non-coding RNAs
miRNA	-	microRNA
MP	-	microparticles
NGS	-	next generation sequencing
PPP	-	platelet-poor plasma
PRP	-	platelet-rich plasma
qPCR	-	quantitative polymerase chain reaction

## Introduction

Platelets play a key role in hemostasis, initiating and propagating thrombosis.<sup>1</sup> Dysregulation and inappropriate activation of platelets underpins a wide range of important diseases, including stroke and myocardial infarction, whereas impairment of platelet function results in bleeding disorders. Platelets are anucleate, and were previously considered to be simple cytoplasmic fragments of megakaryocytes. We now know that platelets house an array of molecules including proteins, RNA and the subcellular machinery of *de novo* protein synthesis. Platelets can synthesize new proteins, such as the integrin alpha3 (glycoprotein-IIIa) protein and the fibrinogen receptor.<sup>2,3</sup> Platelets contain messenger RNA (mRNA) which codes for around a third of human genes.<sup>4,5</sup> More recently, the discoveries that platelets are an abundant source of microRNAs (miRNA)<sup>6</sup>, and that miRNA expression profiles within platelets correlate with platelet reactivity<sup>7</sup>, raised the exciting possibility of novel therapeutic targets and disease biomarkers.

Initial studies by Mitchell et al revealed that not all miRNAs in the circulation are intracellular.<sup>8</sup> This pool of extra-cellular 'circulating miRNA' consists of miRNA within microvesicles, exosomes, or bound to proteins. The finding that miRNAs can also be measured in cell-free serum and plasma was surprising, given their high RNase activity. Compared to mRNAs, miRNAs remain relatively stable in the circulation through several protective mechanisms; association with binding proteins, lipoproteins, or housing in shed microvesicles such as exosomes or microparticles (MPs).<sup>9-12</sup> Platelets release MPs, particularly during activation. These vesicles contain a host of proteins, inflammatory mediators, and non-coding RNAs.<sup>13-15</sup> Microvesicles might be taken up by other cells, introducing another layer of complexity in terms of intercellular signaling by potentially allowing direct regulation of the recipient cell's mRNA profile and gene expression.<sup>16,17</sup> Given this emerging role for circulating miRNAs, plasma and serum miRNA profiles may find use in clinical practice as novel markers of disease, organ function and prognosis.<sup>18</sup>

In this review we bring together nearly a decade's experience with circulating non-coding RNAs, with particular focus on platelet-derived and associated miRNAs, YRNAs, long non-coding RNAs, and circular RNAs. We conducted a literature search in PubMed as queried on the 23<sup>rd</sup> November 2016 using the search terms "*platelet\* AND (miRNA[MeSH Terms] OR micro RNA[MeSH Terms] OR micro-RNA OR microRNA)*". 434 results were retrieved, of which 75 were relevant primary research papers, and 39 were relevant literature reviews. From the literature to date, we collate the known platelet repertoire of non-coding RNAs and contemplate their physiological significance. We also examine their disease associations and potential clinical applications. Finally, we discuss the practical challenges in measuring and comparing miRNA levels, highlighting obstacles that will need to be overcome for this relatively new field to come of age.

## Non-coding RNAs in platelets and the circulation

Different non-coding RNAs have been described (**Figure 1**):

**miRNAs.** The human genome codes for small (~22 nucleotide) regulatory RNA molecules, termed miRNAs or miRs. Since miRNAs were first discovered in 1993, over 2500 have been defined, comprising 1–5% of mammalian genes.<sup>19,20</sup> They are highly evolutionarily conserved and important in the posttranscriptional regulation of protein expression – about one third to half of the human genes is estimated to be regulated by miRNAs.<sup>21-23</sup> MiRNAs act by imperfect Watson-Crick base pairing to the 3'-UTR of target mRNA to affect translation or induce degradation.<sup>24,25</sup> MiRNAs can be expressed as standalone scripts or alongside the parent gene mRNA. In either case, the primary miRNA transcript is processed by the nuclear microprocessor complex consisting of the endoribonuclease Drosha and the double-stranded RNA-binding protein Pasha/DGCR8.<sup>26,27</sup>

The resultant “hairpin” pre-miRNA is then transferred to the cytoplasm by the nuclear membrane protein exportin-5 and further processed by the endoribonuclease Dicer.<sup>28</sup> The resulting mature miRNA duplex associates with an Argonaute (Ago) protein which unwinds the double strand and incorporates one of the two complementary miRNA strands, forming the RNA-induced silencing complex.<sup>29</sup> The RNA-induced silencing complex stabilizes the miRNA strand and guides it to its target mRNA. Since platelets do not have a nucleus and thus cannot transcribe miRNAs, it is currently thought that the platelets inherit their miRNA content during the shedding process from megakaryocytes.<sup>30</sup> Thus, the platelet “miRNAome” in the circulation may provide insights into megakaryocyte function in the bone marrow.

There are many more miRNAs encoded in the human genome than there are detectable in the circulation.<sup>31</sup> For example, we detected >200 miRNAs using next generation sequencing (NGS) in plasma samples.<sup>32</sup> Detectable miRNAs greatly vary in abundance. Not all miRNAs that are present in the circulation can be consistently quantified with cycle threshold (Ct) values of <32 by qPCR, even after pre-amplification. Another striking observation is the high correlation among the abundant circulating miRNAs.<sup>33</sup> This may be due to their common platelet origin: in response to anti-platelet drugs, circulating levels of many miRNAs are reduced in platelet-poor plasma (PPP).<sup>34</sup> Research into miRNAs is hampered by the current lack of functional miRNA data in bioinformatics resources. Access to cataloged experimental data is crucial to enable simple questions to be asked, such as “Which miRNAs are present in the circulation?”, as well as the ability to perform sophisticated pathway and network analyses.<sup>35</sup> This lack of freely accessible data is being addressed by the addition of Gene Ontology (GO) annotations for cardiovascular-related miRNAs.<sup>36,37</sup> In order to answer the question of circulatory miRNAs, we have created GO annotations for those miRNAs identified as being present in human plasma from our previous study.<sup>32</sup> In the parlance of GO, the annotations were created using the GO term “extracellular space” (GO:0005615) with the addition of contextual information describing the extracellular space as part of blood plasma (using the Uber Ontology term Uberon:0001969). A large number of miRNAs were identified in PPP and platelet-rich plasma (PRP).<sup>32</sup> For those with marked enrichment in PRP, as well as significantly increased levels in a platelet spike-in experiment, we were additionally able to include in the annotation that the miRNAs present in the extracellular space are likely to have originated from platelets (using the Cell Ontology term CL:0000233). In total, we have identified 230 human miRNAs as present in the circulation and the annotations providing this information are available in the GO database.<sup>38</sup> Inclusion of functional annotations such as these into public databases will enable researchers to find and analyze miRNA data more easily, allowing for faster progression of their research.

**YRNAs.** In our most recent study, we have also identified YRNAs as another species of circulating non-coding RNAs that is platelet-derived.<sup>32</sup> YRNAs are small non-coding RNAs, approximately 100 nucleotides in length, that are derived from 4 human genes (RNY1, RNY3, RNY4, RNY5 and about 900 pseudogenes).<sup>39,40</sup> Using NGS in PPP and PRP, we observed a dominant peak at sequences of 32-33 nucleotides long, which was mapped to YRNA genes (**Figure 2A**).<sup>32</sup> The full-length YRNAs have cytoplasmic or nuclear localization and are involved in the initiation of DNA replication as well as in ribosomal RNA quality control.<sup>41,42</sup> They are components of Ro ribonucleoproteins, which constitute important autoantigens in autoimmune diseases such as systemic lupus erythematosus and Sjögren’s syndrome.<sup>43</sup> YRNA fragments are present in the circulation, with 5’ fragments being much more abundant than 3’ fragments for the majority of RNY genes.<sup>32,44</sup> YRNA fragments are generated during cell stress or apoptosis. Given that YRNA fragments are abundant in platelets, and strongly correlate to platelet-derived proteins (**Figure 2B**) and miRNAs in the circulation<sup>32</sup>, we speculate that the YRNA fragments are formed during the budding of platelets from megakaryocytes. In common with miRNAs, the YRNA fragments bind Ago proteins but do not seem to mediate target repression. However, in contrast to the processing of mature miRNAs from precursor miRNAs, YRNA fragments are generated by a

Dicer-independent mechanism.<sup>45</sup> The predominant platelet origin of YRNA fragments in human plasma is further supported by the results from platelet spike-in experiments.<sup>32</sup>

**Ribosomal RNA.** Ribosomal RNA (rRNA) is a key regulator of intracellular protein synthesis, and is also detected in the circulation. Tissue damage and unregulated cell death result in significant quantities of rRNA shifting into the extracellular compartment.<sup>46,47</sup> As reviewed recently<sup>48</sup>, rRNA is thought to be able to act as a protein cofactor or template for enzyme rRNA. This may have several important pathophysiological roles in atherosclerotic plaques, including promotion of vascular hyperpermeability, initiation of coagulation and thrombus formation, recruitment of leukocytes, promotion of a pro-inflammatory phenotype of monocytes/macrophages, and promotion of cardiomyocyte death. The potential role of rRNA as a predictor of cardiovascular disease has not been addressed yet.

**Long non-coding RNAs.** Recently, attention has shifted from small non-coding to long non-coding RNAs (lncRNAs). Unlike miRNAs and YRNAs, which are mainly found in the cytosol, lncRNAs are predominantly retained in the nucleus.<sup>49</sup> This nuclear localization has important implications for their release mechanism. While miRNAs and YRNAs are secreted as part of any budding process of microvesicles with cytoplasmic components, even in the absence of injury, the secretion of lncRNAs may be dependent on cellular damage that is sufficient to release nuclear material. Upon release, the lncRNAs require protection from RNase degradation. In general, lncRNAs may be more susceptible to RNase activity than small non-coding RNAs as the longer sequence is more vulnerable to cleavage and not as easily complexed and protected by RNA-binding proteins. Whereas lncRNAs are readily detected in full blood, levels in plasma or serum tend to be low, at least in healthy individuals without tissue injury. The release of mitochondria-associated lncRNAs has been described in patients with myocardial infarction.<sup>50</sup> It is possible that mitochondrial lncRNAs are protected from RNase degradation. Further, as cardiomyocytes are particularly rich in mitochondria, these lncRNAs may indeed be cardiac-derived. However, unlike troponins, lncRNAs are not cardiac-specific, so contributions from other cell types cannot be excluded.<sup>51</sup> Since platelets are anuclear and have a low mitochondrial content, most lncRNAs may not be detectable in platelets, with the notable exception of circular RNAs (circRNAs).

**Circular RNAs.** Recent evidence suggests that platelets are relatively abundant in circRNAs<sup>52</sup>, an emerging class of noncoding RNAs that had been described as early as 1976.<sup>53</sup> Development of advanced NGS techniques led to their recent rediscovery<sup>54</sup>, showing ubiquitous expression in both humans and mice.<sup>55</sup> Several pathways exist to generate circRNAs.<sup>56</sup> Most commonly, they are derived from exons of protein-coding genes through back-splicing, while some arise from intronic or intergenic regions via alternative splicing. circRNAs are generally localized in the cytoplasm, but how they are exported from the nucleus remains unknown. RNA-binding proteins like Quaking and Muscleblind are thought to affect the abundance of circRNAs in human cells through binding of the specific RNA-binding proteins to flanking intronic sequence motifs. Interaction between the RNA-binding proteins on each end approximates both ends of the exon and facilitates the formation of a circle. Quaking regulates human circRNA biogenesis, and knockdown of Quaking decreases the expression of abundant circRNAs.<sup>57</sup> CircRNAs were found to be enriched in platelets, where they are generated by exon back-splicing.<sup>52</sup> Using RNase R to selectively remove linear transcripts, several distinct circRNAs were identified in the platelets. Although the majority of circRNAs are not cell type-specific, human platelets and erythrocytes were found to be highly enriched for circRNAs compared to nucleated cell types. Several circRNAs were expressed at much higher levels than the linear form of the RNA in platelets and erythrocytes. Interestingly, the relative proportion of circRNAs in cultured megakaryocytes is much lower compared to mature platelets. Combined with the finding that circRNA decays at a significantly slower rate than linear RNA, and platelets lose more than 90% of their progenitor mRNA, the enrichment of circRNA in platelets might be

the result of linear RNA degradation.<sup>52</sup> This process has a profound effect on the composition of RNA, as anucleate platelets cannot transcribe new RNA. Recent reports demonstrated that circRNAs can serve as miRNA sponges, which are believed to negatively regulate miRNAs by sequestering miRNA molecules.<sup>58</sup> This raises questions of how circRNAs interact with miRNAs and mRNAs in platelets, and how circRNA transcripts are formed in platelets. With their enrichment being a signature of mRNA decay, platelet circRNAs may reflect platelet function or ageing.

### The miRNA repertoire of platelets

Landry et al first reported a large number of platelet miRNAs by using locked nucleic acid (LNA)-based microarray profiling.<sup>6</sup> NGS has enabled the discovery of novel miRNA species. Plé et al identified nearly 500 species, with the let-7 family of miRNAs comprising nearly 50% of the total.<sup>59</sup> Since then, Bray et al have identified many more, bringing the total of recognized platelet miRNAs to around 750.<sup>4</sup> The variation in reported platelet miRNA expression is not solely due to inter-individual differences such as gender and age.<sup>60</sup> Sample preparation, storage, normalization procedures and measurement platforms play an important role. Studies aimed at defining the platelet miRNA profile use a variety of techniques, including micro-arrays, qPCR-based methods and NGS. For example, Wang et al demonstrated platform-associated amplification differences in miR-107, which showed much higher amplification with LNA-based assays compared to TaqMan assays.<sup>61</sup> In clinical laboratory conditions, Yu et al showed upregulation of several apoptosis-related platelet miRNAs after prolonged blood bank storage of platelets.<sup>62</sup> As platelet preparation from whole blood can lead to contamination with leukocytes and erythrocytes, themselves abundant sources of miRNAs, controlling cellular contamination of platelet preparations is essential.<sup>61</sup> Variation in preparation and storage conditions can drastically affect platelet miRNA expression which may explain why inter-study miRNA expression ranks are highly variable. Based on the current literature, a combined inter-study miRNA expression rank list is presented in **Figure 3**.

### Association of platelet miRNAs with disease

Antiplatelet drugs reduce the risk of cardiovascular events, but patients on antiplatelet therapy still suffer thrombotic events. Ever more potent antiplatelet strategies carry the risk of bleeding complications. Ideally, a “sweet spot” could be defined for each patient that offers maximum platelet inhibition with minimal bleeding risk.<sup>63</sup> For optimal platelet inhibition, platelet turn-over is important: with a life span of 7-9 days, 10-15% of the platelet pool must be replenished every day, equivalent to  $10^{10}$  -  $10^{11}$  platelets per day.<sup>64</sup> The platelet turnover rate may be important for the efficiency of drugs like aspirin with a short half-life. Aspirin irreversibly binds cyclooxygenase so is effective for the full lifespan of the platelet. However, increased platelet turnover can lead to more budding of new platelets without inactive cyclooxygenase between doses. Furthermore, newly formed platelets are larger, more reticulated, more reactive, and more prone to participate in thrombus formation compared to older platelets. They also contain a higher amount of RNA and are more able to produce proteins, in particular alpha granule proteins. Counting the subset of reticulated platelets may be a parameter for platelet turnover. However, the intrinsic properties of platelets could be even more important for platelet reactivity than their turnover rate.<sup>65</sup> In light of the enrichment of miRNAs and circRNAs, and the described effects of mRNA degradation during the lifetime of platelets, the noncoding RNA content of platelets may better reflect their intrinsic properties.

Platelet miRNA expression profiles in healthy volunteers remain stable over the life span of a platelet.<sup>66</sup> This expression profile is significantly altered in various disease states including myocardial infarction<sup>67,68</sup>, diabetes<sup>69</sup>, and cancer.<sup>70</sup> There is, therefore, the

opportunity to find new biomarkers or therapeutic targets, and increase our understanding of the pathophysiological mechanisms of these diseases. Anucleate platelets lack transcriptional control, so differences in miRNA signatures during platelet-activating disease states have been ascribed to a number of mechanisms: shedding of MPs<sup>71</sup>, synthesis of mature miRNA from precursor miRNAs<sup>69</sup>, and post-transcriptional modifications.<sup>59</sup> We undertook the first systematic analysis of circulating miRNAs in a large population-based study (the Bruneck study) and revealed a loss of miRNAs in type 2 diabetes mellitus.<sup>72</sup> Subsequent studies indicated that this loss may be attributed to activation of calpain, which can affect platelet levels of Dicer.<sup>73</sup> As this endoribonuclease is key in the processing of precursor miRNAs to mature miRNAs, its loss resulted in decreased levels of several platelet-enriched miRNAs.<sup>69,74</sup> These findings are in line with studies showing that circulating miRNA changes in cardiovascular risk can be attributed to platelets.<sup>32,34</sup> Additionally, we demonstrated that a combination of miRNAs may predict future cardiovascular events.<sup>75</sup> This has been confirmed by other investigators.<sup>76</sup> In continuation of our work on circulating miRNAs in diabetes<sup>72</sup>, we have identified two angiogenic miRNAs as biomarkers for diabetic retinopathy.<sup>77</sup>

Findings by other investigators and our group suggest that platelet miRNAs might not only reflect but also *affect* platelet function:

**miR-96 and VAMP8.** In 2010, Kondkar et al reported a role for miR-96 in platelet reactivity.<sup>78</sup> They showed that miR-96 may act through regulation of vesicle-associated membrane protein 8 (VAMP8), an important SNARE protein involved in platelet degranulation. Healthy volunteers' platelets were categorized as either hyper- or hypo-reactive. mRNA profiling revealed differential expression of a range of scripts, including VAMP8 mRNA (4.8-fold decrease in the hypo-reactive versus hyper-reactive platelets). This translated to a 2.5-fold lower VAMP8 protein expression in the hypo-reactive platelets. miR-96 levels were upregulated in hypo-reactive platelets (2.6-fold higher). Transfection of VAMP8-expressing HCT cells with miR-96 was associated with dose-dependent reductions in VAMP8 mRNA and protein levels; a similar finding was reported in cells of a megakaryocyte lineage. miR-96 was predicted to bind the 3' UTR of VAMP8. In contrast with this study, Shi et al reported no association between platelet response to clopidogrel and miR-96 expression, and miR-96 was not amongst the most highly expressed miRNAs found in human platelets.<sup>79</sup> Although this does not discredit a role for miR-96 in regulating platelet reactivity, these findings need to be validated and explained in a larger study.

**MiR-376c, miR-599 and platelet phosphatidylcholine transfer protein.** There is a racial disparity in survival in coronary heart disease between patients with Caucasian and Afro-Caribbean background, even after adjusting for all known factors. Edelstein et al investigated whether racial difference in platelet function underpins an increased thrombotic risk.<sup>80</sup> 154 healthy black and white volunteers were recruited and platelet reactivity to thrombin was measured. Higher aggregation and platelet calcium responses to PAR4 (thrombin receptor 4) in Afro-Caribbean individuals were found. Phosphatidylcholine transfer protein (PCTP)-encoding mRNA was found to be upregulated in Afro-Caribbeans. After profiling platelet miRNA signatures, 178 miRNAs, including miR-376c, were predicted to target PCTP mRNA. miR-376c levels inversely correlated with PCTP mRNA levels, PCTP protein levels, and PAR4 reactivity. miR-376c is part of a cluster of miRNAs differentially expressed by ethnic origin, which may underpin differences in platelet function. Interestingly, a statistical cluster of 24 miRNAs all mapped to chromosome 14q32.2. Among other differentially expressed miRNA were some of the most abundant platelet miRNAs: miR-223, -21, -23b, -107, and let-7c. Plé et al also found evidence of miRNA regulation of PCTP.<sup>59</sup> Their analysis predicted miR-599 targeting of the 3'UTR of PCTP mRNA, and showed downregulation of a reporter gene containing the PCTP 3'UTR in HEK293 cells transfected with pre-miR-599.



**miR-223 and P2Y<sub>12</sub> receptor expression.** miR-223 is highly expressed in platelets and megakaryocytes, where it is thought to regulate thrombopoiesis. One of the most interesting features of miR-223 is its ability to bind to the 3'UTR of human P2Y<sub>12</sub> receptor mRNA.<sup>6</sup> The P2Y<sub>12</sub> receptor mediates important platelet functions, including aggregation and granule secretion, and is activated by ADP, the physiological agonist of this G<sub>i2</sub> protein-coupled receptor.<sup>81</sup> Landry et al showed that platelet P2Y<sub>12</sub> receptor mRNA co-precipitates with Ago2, suggesting that miR-223 could regulate receptor levels and thereby platelet function.<sup>6</sup> Platelet response to ADP antagonists is clinically relevant given the widespread use of drugs such as clopidogrel, prasugrel, and ticagrelor in the prevention and treatment of myocardial infarction and ischemic stroke.

Due to the proposed regulation of P2Y<sub>12</sub> receptor function, miR-223 has been the focus of many clinically orientated studies. In particular, there is great interest in relation to platelet responsiveness to clopidogrel, a prodrug which requires hepatic cytochrome P450 enzymes to become active. Shi et al reported decreased levels of platelet miR-223 in association with high platelet reactivity despite treatment with clopidogrel.<sup>79</sup> They looked at patients presenting with non-ST elevation acute coronary syndrome, in terms of their platelet reactivity index, who were treated with aspirin and clopidogrel. In patients who had a reduced response to clopidogrel, platelet miR-223 was significantly downregulated, whereas miR-96 was unchanged. Platelet miR-223 also inversely correlated with the platelet reactivity index. Of note, neither miR-223 nor miR-96 was significantly different between normal and low responders when ADP-induced platelet aggregometry was used. These results suggest platelet miR-223 may be a predictor of normal and low responders to clopidogrel. This may be supported by the fact that P2Y<sub>12</sub> mRNA can be found in Ago2 immunoprecipitates.<sup>6</sup>

In a preliminary report including 21 males presenting with non-ST elevation acute coronary syndrome, Chyrchel et al studied miR-223 plasma levels. Patients were treated with aspirin plus either clopidogrel, prasugrel, or ticagrelor. Although there were no differences in plasma miR-223 levels between drug type, when all the data was pooled miR-223 positively correlated with the level of platelet inhibition.<sup>82</sup> These results seem in line with those of Shi et al who found that high platelet miR-223 levels predicted efficacious platelet inhibition with clopidogrel.<sup>79</sup> Similarly, Zhang et al report decreased plasma miR-223 to be associated with clopidogrel "low-responders".<sup>83</sup> In this study of 62 patients with unstable angina, miR-223 was found to be the only independent predictor of low responders to clopidogrel, and was higher with greater degrees of platelet inhibition.

miR-223 is also expressed in mouse platelets. In response to high agonist concentrations, miR-223 knock-out mice do not show any detectable alteration in aggregation, speed of clot retraction, platelet adhesion, or bleeding time. P2Y<sub>12</sub> mRNA expression levels are also unchanged.<sup>84</sup> This is probably due to mouse P2Y<sub>12</sub> mRNA lacking the specific binding site for miR-223, rendering mouse models difficult to interpret in this context. Nonetheless, Elgheznawy et al subsequently demonstrated that miR-223 deletion in mice did result in modestly higher platelet activation at lower agonist concentrations.<sup>69</sup> Proteomic analysis revealed differential expression of kindlin-3 and coagulation factor XIII-A in platelets from miR-223 deficient mice.

Zampetaki et al found that serum miR-223 levels are inversely associated with risk of future myocardial infarction, and showed a stronger association with fatal than non-fatal events.<sup>75</sup> Badrnya et al showed reduced platelet microvesicle miR-223 in smokers.<sup>85</sup> These findings are potentially complementary to those relating low platelet miR-223 level to increased P2Y<sub>12</sub> activity in men, and to those showing higher platelet reactivity in response to miR-223 deletion in mice. Subsequent clinical studies have investigated platelet miR-223, including in a small cohort of patients who suffered an ischemic stroke. Duan et al report that platelet miR-223 and -146a were lower in stroke patients with diabetes versus controls.<sup>86</sup> Platelet miR-223 and -146a levels significantly correlated with platelet reactivity as

measured by P-selectin expression and also correlated to plasma levels, suggesting that platelets are a major source of circulating miR-223.

In summary, miR-223 targets the 3'UTR of the human P2Y<sub>12</sub> platelet receptor mRNA. The P2Y<sub>12</sub> receptor is important in platelet activation and is the target of many drugs used to inhibit platelet function. Lower levels of platelet miR-223 therefore may result in more P2Y<sub>12</sub> receptor activity and thus higher platelet reactivity. In this way, lower platelet miR-223 levels may increase the risk of thrombotic disease such as myocardial infarction. This also may underpin the observation that lower platelet miR-223 levels are associated with reduced efficacy of P2Y<sub>12</sub> receptor antagonists such as clopidogrel. Mice lack the specific miR-223 binding site on the P2Y<sub>12</sub> mRNA and so comparisons to human data is difficult. Nonetheless, miR-223 deficient mice do seem to have altered platelet function, perhaps through regulation of other platelet proteins involved in clotting.

**miR-126 and ADAM9.** Changes in circulating miR-126 may also reflect platelet activity rather than endothelial dysfunction. Early studies, including one from our group<sup>72</sup>, stated that miR-126 is endothelial-specific. Whereas miR-126 is enriched in endothelial cells and supports endothelial integrity, its circulating levels cannot be attributed solely to endothelial cells. In fact, megakaryocytes and endothelial cells both express miR-126, and circulating miR-126 levels appear to be predominantly platelet-derived.<sup>34,77</sup>

De Boer et al investigated the effects of aspirin on the platelet contribution of circulating miR-126 in patients with type 2 diabetes. PRP from subjects was treated with either arachidonic acid (a platelet activator), or, arachidonic acid plus aspirin. Once the PRP had been treated it was centrifuged to separate the platelets from the now platelet-poor plasma. Platelet activation resulted in a considerable transfer of miR-126 to the PPP fraction and this could be rescued with the addition of aspirin. miR-223, -16, and -423 showed a similar pattern suggesting that they are all released from platelets upon activation and that aspirin attenuates this release. miR-126 levels also correlated with platelet activation as measured by soluble P-selectin. As part of another clinical trial involving patients with type 2 diabetes, the platelet activation state (measured via P-selectin expression) was assessed in 40 patients treated with increasing doses of aspirin. Platelet activation positively correlated with plasma miR-126 and aspirin reduced circulating levels of miRNA-126. Arguing against an endothelial origin of miR-126, the authors point out that aspirin primarily inhibits platelet-enriched COX-1, whereas the endothelium predominantly expresses COX-2. They also demonstrated no change in circulating von Willebrand factor.<sup>87</sup> Taken together, these findings suggest that aspirin has the potential to significantly alter the miRNA signature of plasma and careful consideration should be given when designing clinical studies in pursuit of novel biomarkers.

In our experiments, we demonstrated that plasma miR-126 levels 1) correlate to platelet MPs, 2) are reduced upon platelet inhibition and 3) are associated with markers of platelet activation in the general population.<sup>32</sup> These associations were further substantiated by genetic evidence. The single nucleotide polymorphism (SNP) rs4636297 is located in the primary transcript-encoding region of miR-126 and affects its processing to mature miR-126. The minor allele is associated with increased processing of the primary miRNA to mature miR-126. In a population-based study, carriers of the minor allele had higher levels of miR-126 in plasma and in serum.<sup>32</sup> The increase in circulating miR-126 was associated with a rise in platelet activation markers such as platelet factor 4 and pro-platelet basic protein. The genetic data on miR-126 and platelet function were in line with findings in the Bruneck cohort, in which miR-126 serum levels were positively associated with risk of myocardial infarction after adjustment for miR-223 and miR-197, again with platelets being identified as the most probable source.<sup>75</sup> A study by Yu et al showed that higher plasma miR-126 predicted major adverse cardiac events in 491 patients after a percutaneous coronary intervention, while on dual antiplatelet therapy.<sup>88</sup>

In mice, inhibition of miR-126 by antagomiRs (synthetic inhibitors of miRNAs) decreased thromboxane A<sub>2</sub>-dependent platelet aggregation. This effect is likely due to megakaryocyte miR-126, but since antagomiRs are administered systemically, the contribution of other cell types, in particular endothelial cells, cannot be excluded. However, inhibition of miR-126 expression in endothelial cells would be expected to result in endothelial dysfunction and increased platelet activation. Similarly, if the effects of the SNP rs4636297 were limited to endothelial cells, one might expect that higher miR-126 levels are protective for endothelial cells and thus reduce platelet activity. The opposite was observed in mice and men. In MEG-01 cells, a human megakaryocyte cell line, ADAM metallopeptidase domain 9 (ADAM9) was confirmed as a direct miR-126 target that attenuates the adhesion of platelets to collagen. Inhibition of miR-126 by antagomiRs also had indirect effects on P2Y<sub>12</sub> expression levels, at least in mice. Thus, in addition to endothelial cells, miR-126 affects megakaryocytes. It remains to be seen whether platelet-specific deletion of miR-126 can recapitulate the accelerated atherosclerosis phenotype seen in miR-126-deficient mice.<sup>89</sup>

In summary, higher plasma or serum levels of miR-126 are associated with an increased risk of myocardial infarction and other major adverse cardiac events. This may, at least in part, occur via increased platelet activation. Inhibition of miR-126 with antagomiR-126 reduces platelet activation in mice, which may be explained by blocking of ADAM9's negative effect on platelet:collagen adhesion or via indirectly affecting platelet P2Y<sub>12</sub> expression levels.

### Cellular crosstalk via miRNAs?

Several studies suggest that secreted miRNAs may act as paracrine mediators. The concept is appealing, but most evidence is currently limited to *in vitro* studies. By overexpressing a miRNA in one cell type, harvesting microvesicles from the conditioned media and adding these microvesicles to recipient cells, miRNA transfer and downregulation of miRNA targets is detectable, suggesting that the miRNA uptake has biological function. There are several caveats to these *in vitro* studies:

- 1) MiRNAs are not very abundant in the circulation and pre-amplification is usually required for all but the most abundant miRNAs for reliable detection by qPCR. It is difficult to envisage how the few copy numbers of miRNAs would have a potent effect on target gene expression. The amount of circulating miRNAs is several orders of magnitude below the cellular miRNA content, and exogenous miRNAs would have to compete with the endogenous miRNAs in the recipient cells for loading into the RNA-induced silencing complex. Unless there is a receptor that recognizes miRNAs and initiates a downstream signaling cascade, it is difficult to envisage how uptake of exogenous miRNAs could mediate biological effects.
- 2) MPs and exosomes are rich in proteins. The protein content of microvesicles may be functionally more important than their miRNA load. RNase treatment does not unambiguously prove that the observed biological effect is due to miRNAs. Protein degradation may also occur during the RNase digestion step.
- 3) In situ hybridization studies for a particular miRNA tend to reveal a characteristic staining pattern. For example, staining for miR-126 is confined to endothelial cells, whereas staining for miR-143 and miR-145 is observed in vascular smooth muscle cells. If miRNA transfer were a common phenomenon, such specificity would not be detected, and a more homogenous staining pattern would be expected.
- 4) Importantly, the tissue architecture, including basement membranes and extracellular matrix, should act as a physical barrier for the exchange of microvesicles.
- 5) Routine cell culture uses fetal calf serum, which is a source of microvesicles.

Thus, we currently lack convincing evidence that the exchange of miRNAs is more than an *in vitro* phenomenon. In uninjured tissues, the cellular miRNA exchange might be low. It is conceivable that a miRNA transfer could occur under pathological conditions, such as platelet activation and clearance by inflammatory cells. Several experiments shed light on the role of platelet miRNA as a putative paracrine regulator of cellular function via regulation of others cells' mRNA and protein expression. For abundant platelet miRNAs, such as miR-223, target genes have been described, many of which are associated with inflammation. This miRNA is also expressed in leukocytes, further indicating a potential role. Given that platelets are already heavily implicated in several disease processes with an inflammatory basis, an interplay between endothelial cells, leukocytes, monocytes, and other cells types by endogenous and transferred miRNA seems plausible and an important area for further investigation.

Jansen et al sought to define the miRNA content of circulating microvesicles and vesicle-free plasma in 181 patients with stable coronary artery disease undergoing coronary angiography.<sup>90</sup> Over 6 years follow-up, microvesicle miR-126 and miR-199a levels above the median were associated with significantly fewer major adverse cardiac events and percutaneous coronary interventions. There was no association between miRNAs from PPP and cardiovascular events. Microvesicle miR-126 was significantly reduced, and 199a trended towards reduction, in coronary artery disease patients versus age-matched controls. Again, no such difference was found in the PPP. Through microvesicle typing of surface markers, they established that miR-126 expression is highest in CD31<sup>+</sup>/CD42b<sup>-</sup> microvesicles (i.e. endothelial), consistent with known expression patterns in endothelial cells, and miR-199a is highest in CD31<sup>+</sup>/CD42b<sup>+</sup> microvesicles (i.e. megakaryocyte-derived). These results are in contrast to results for circulating miR-126 levels. However, this study by Jansen et al looked specifically at the microvesicular compartment, making cross-study comparisons difficult.

Laffont et al showed that activated platelets can deliver regulatory Ago2-miRNA complexes to endothelial cells, and that this occurs via MPs. First, they confirmed that activated platelets release substantially more MPs than quiescent platelets. Profiling the miRNA content of the MPs showed that the miR-223 content was greatly increased after platelet activation, suggesting selective packaging of miRNAs into platelet MPs. They then showed that the MPs contain functional Ago2:miR-223 complexes which could cleave a complementary miR-223 RNA sensor, suggesting these complexes are functionally relevant. Next, they used fluorescently labeled MPs to demonstrate internalization by human umbilical vein endothelial cells. Endothelial miR-223 levels increased 22-fold after incubation with MPs for 1 hour, an effect which persisted for 48 hours. Again addressing functional relevance, endothelial cells demonstrated a 44% reduction in a transfected reporter gene under miR-223 control when incubated with MPs. Significant downregulation of endogenous RNA levels occurred within 6 hours of exposure to platelet MPs, an effect which was rescued with the addition of a miR-223-neutralizing "sponge".<sup>17</sup>

Pan et al also showed increased MP release and MP miRNA enrichment after platelet activation. In the apolipoprotein E null mouse model of atherosclerosis, MP miR-223 content was higher than in controls. This finding was also tested in a small selection of human patients, in whom miR-223 expression was higher in platelets and MPs of patients with inflammatory diseases compared to healthy controls. The authors demonstrated that endothelial cells take up MPs in an ATP-dependent manner, and endothelial miR-223 levels increase without an increase in pre-miR-223, suggesting that the increase was not due to *de novo* synthesis in recipient cells. Both a miR-223 mimic, and incubation with MPs, were shown to reduce insulin-like growth factor 1 receptor protein levels. This effect was blocked by anti-miR-223. miR-223 delivery increased advanced glycation end products-induced apoptosis, potentially via reduced levels of the insulin-like growth factor 1 receptor.<sup>91</sup>

Finally, Gidlöf et al showed that patients with ST-elevation myocardial infarction had reduced levels of miR-22, -185, -320b, and -423-5p in platelets compared to controls, and an even greater reduction in aspirated coronary artery thrombus.<sup>67</sup> The authors concluded that this is due to platelet activation and miRNA release. *In vitro* they demonstrated miR-22, -185, -320b, and -423-5p release into the supernatant after thrombin-induced platelet activation. Using platelets transfected with a scrambled, fluorescently labeled miRNA, they showed effective transfer to endothelial cells when incubated with activated platelets. Furthermore, this was shown to be MP-dependent as the addition of brefeldin A (a vesicle formation inhibitor) prevented miRNA transfer. Overexpression of miR-22 and miR-320b in endothelial cells suggested these miRNAs were involved in the regulation of intercellular adhesion molecule 1 (ICAM1). When endothelial cells were incubated with platelet releasate, ICAM1 expression was downregulated by 30%. Knockdown of endogenous endothelial miR-22 and miR-320b caused an increase in ICAM1 expression, confirming that the effect was due to MP miR-22 and/or miR-320b. Interestingly, this could be rescued by incubating the cells with platelet releasate.

In summary, there is now good evidence that 1) platelets transfer miRNA, and 2) that this is mediated by MPs.<sup>92,93</sup> However, it is less certain whether this transfer is functionally relevant at physiological concentrations *in vivo* and to what extent the observed effects are mediated by the miRNA content rather than the protein content of the platelet MP material. Although most studies have focused on platelet transfer of miRNA to endothelial cells, Risitano et al showed that RNA transfer can occur between circulating platelets and monocytes.<sup>71</sup>

### Guidance on how to measure circulating miRNAs

Research on circulating miRNAs is attracting increasing attention, as non-coding RNAs may constitute an entirely new entity of biomarkers. A prerequisite for advances in this area is the generation of comparative data by independent groups. To help this we have suggested a set of minimum reporting standards and recommended methods for circulating miRNA data (**Table 1**).

**Plasma or serum?** A fundamental question is the choice of plasma or serum for measuring miRNAs (**Figure 4**). The origin of miRNAs in plasma and serum may not be the same, as platelets are activated during clotting and may contribute a larger proportion of miRNAs compared to plasma. In plasma, the cells are removed by centrifugation in the presence of an anti-coagulant. Citrate and EDTA are the preferred anticoagulants. Heparin plasma, for the reasons outlined below, is less suitable for miRNA measurements. Platelet activation during plasma centrifugation is another concern. Serum, on the other hand, is obtained by clotting blood at room temperature for 30 min to 1 h. The clotting process involves the activation of thrombin, which cleaves fibrinogen to fibrin. Thrombin is a protease and its substrate specificity is not restricted to fibrinogen. The coagulation cascade involves a series of proteases, which may degrade carrier proteins of miRNAs. This might result in a loss of miRNAs, which can be mitigated by adding RNase inhibitors.<sup>94</sup> If platelets release miRNAs upon activation, then findings in plasma and serum might give opposite results: plasma miRNAs may reflect the platelet release prior to blood sampling, whereas serum miRNAs may reflect the extracellular and platelet miRNA content combined - the more release, the less content. Thus, for our most recent studies, we used PPP, which we believe to be the best samples for linking miRNAs to in-vivo platelet activation.

**Platelets, microvesicles, and exosomes.** An understanding of which specific fraction of the circulation is being measured, is of the utmost importance for reproducibility and adequate inter-study comparison. Ideally, one would be able to easily separate different circulating compartments: the cellular compartments (erythrocytes, leukocytes, platelets),

the microvesicle compartment, the exosome compartment, and the particle-free compartment devoid of membrane-bound vesicles or cells. Whilst isolating erythrocytes and leukocytes is relatively easy based on their size and density, isolating the smaller and less dense compartments poses a greater challenge. Isolating platelets from platelet-rich plasma is done routinely but requires care in order to avoid activating the platelets during the early centrifugation steps. As platelets release microvesicles upon activation, this could affect the measured miRNAs in platelets as well as plasma.

**Residual platelets.** Platelets contain a substantial amount of miRNAs and are likely to be major contributors to the circulating miRNA pool, as discussed above.<sup>34</sup> This further complicates sample preparation for miRNA analysis: differences in plasma preparation, centrifugation speed, duration of coagulation and the residual platelet content will have impact on multiple miRNAs.<sup>95,96</sup> In RNA extracts from plasma samples, the detection of the platelet- and megakaryocyte-specific transcript Integrin alpha-IIb can be used to assess platelet content. Notably, the expression of Integrin alpha-IIb correlates with the expression of abundant platelet-derived plasma miRNAs (miR-24, -126, -191, -223). If plasma samples have a very high residual platelet content, their miRNA profile may be more similar to serum and reflect predominantly platelet miRNA content rather than platelet miRNA release. Plasma platelet content must be uniform to allow comparisons between samples, as residual platelets may introduce confounding. When plasma samples have already been collected, an additional centrifugation prior to RNA extraction may reduce the platelet content.<sup>95</sup> However, centrifugation of plasma after freezing is still subject to the risk of contamination from platelets lysed during the freeze/thaw cycle. Ideally, a method for the preparation of PPP prior to storage should be used to minimize the effect of residual platelets on miRNA measurements.

**Hemolysis.** Erythrocytes are the most abundant cell type in blood. The rupture of erythrocytes can occur due to high shear forces in the needle during blood collection or improper handling during sample processing. As hemolytic samples contain a high amount of red-blood cell-derived miRNAs, the levels of multiple miRNAs are altered in hemolytic samples.<sup>97</sup> Hemolysis can be assessed in plasma and serum by measuring hemoglobin spectrophotometrically or in the respective RNA extracts by analyzing miRNAs known to be affected by hemolysis such as miR-451.<sup>98</sup> It is advisable to exclude hemolytic samples from further analyses. Alternatively, such compromised samples can only be used for miRNAs of interest that are unaffected by hemolysis.<sup>99</sup>

**Leukocyte contamination.** Cells shed miRNAs via MPs and exosomes into the extracellular space. The miRNA content of the MPs and exosomes differs depending on the stimulus of the parent cells. However, the intracellular concentration of miRNAs is much higher than in plasma or serum. Considering the very low concentration of extracellular, circulating miRNAs, any contamination of plasma or serum samples with cellular material, for example leukocytes, will greatly affect the miRNA profile. Thus, studies reporting a surprisingly large number of circulating miRNAs compared to other publications may have analyzed samples that were contaminated with cellular material.

**Batch effects.** Batch effects can occur when analyzing the expression of miRNAs on multiple qPCR plates. In order to minimize their impact, several precautions should be taken to obtain reliable data: 1) To correct for variability between plates, a calibrator sample should be included across all plates. 2) The same batch of plasticware and reagents such as PCR Mastermix, primers and probes should be used for the entire study cohort. We have previously observed lot-to-lot-variability for miRNA reagents, even from leading manufacturers. 3) Reagents should be aliquoted, as freeze-thaw cycles affect their quality and performance. 4) Samples from different groups should be distributed equally across all batches. These precautions minimize the impact of batch effects and help to obtain more reliable data.

**Endogenous normalization controls.** Normalization procedures should eliminate technical and experimental variation across samples in order to more reliably identify biological differences. In qPCR analysis, normalization controls are used to correct for variability in RNA extraction, reverse-transcription and PCR. Ideally, a normalization control is stably expressed and not affected by experimental conditions or clinical parameters. For the analysis of miRNAs in cells or tissue, small nucleolar RNAs (snRNAs) are routinely used to normalize data. In general, they accurately reflect the small RNA content of a sample, although there are limitations and drawbacks. For example, snRNAs can correlate with cancer pathology and prognosis which can introduce bias when they are used as normalization controls for cancer samples.<sup>100</sup> For circulating miRNAs, however, there is no generally accepted endogenous control. snRNAs are intracellular RNA molecules and their levels in the circulation are very low. U6 RNA has been used as a normalization control in plasma and serum samples but circulating levels of U6 display inter-individual variability and are affected by inflammatory processes, reducing its reliability.<sup>101</sup> Single miRNAs or panels of miRNAs have been used or suggested as endogenous controls: miRNAs that have been used as normalizers include miR-16, miR-21, miR-93, miR-103, miR-191, miR-192, miR-423 and miR-425. These miRNAs, however, may well be affected by other uninvestigated diseases or medications. Anti-platelet therapy, for example, has been demonstrated to lower the circulating levels of plasma-derived miRNAs including miR-21 and miR-191.<sup>34</sup> Alternatively, data can be normalized to the average Ct of multiple or all analyzed miRNAs.<sup>102</sup> Generally, combinations of miRNAs may be a more robust approach, based on the assumption that overall miRNA expression is stable and not affected by disease to the same degree as individual miRNAs. The more miRNAs that are combined, the more robust the control should be. However, this normalization method can be problematic when several of the miRNAs used to normalize are dysregulated in a similar direction, potentially causing false-positive or -negative findings. Therefore, accepting that no better endogenous alternatives exist, neither a single miRNA nor a combination of miRNAs represent the “perfect” normalization control.

**Exogenous normalization controls.** The most commonly used normalization method for circulating miRNA analysis is the use of an exogenous “spike-in” control. For this purpose, synthetic oligonucleotides of miRNA sequences from other species are used, typically from the nematode *Caenorhabditis elegans* (e.g. Cel-miR-39). Such spike-in controls are added in equal amounts to each sample during RNA extraction or reverse transcription. A spike-in control added at the RNA extraction step can normalize for differences in extraction efficiency, reverse transcription or qPCR efficiency, which may be caused by the presence of inhibitors in the sample or pipetting errors. Spike-in controls generally reflect miRNA quantities in different samples, but we have observed that RNA samples display a lower quantity of Cel-miR-39 when they were stored at -80°C for a longer period of time, impairing analysis in older samples. Moreover, heparin medication can affect Cel-miR-39 as well as the measurement of miRNAs, depending on their origin.<sup>103,104</sup> The Cel-miR-39 measurements across samples must be stable. Variability exceeding 0.5-1 Ct values should be cause for concern.

**MiRNA measurements.** The gold standard for miRNA measurements is qPCR. It provides independent and robust amplification and quantitative detection of minute RNA amounts across the wide dynamic range of miRNA expression levels. Among the drawbacks of the technology is the fact that its high-throughput capabilities are limited. We have previously compared commercial qPCR assays and obtained good agreement between assays from two suppliers, for individual Taqman miRNA assays and customized qPCR plates from Exiqon. For customized qPCR plates, however, there is the possibility that variations in the manufacturing process remain undetected. This is less likely to occur in standard miRNA assays as multiple users will rapidly detect manufacturing problems. Thus, it is important to know the expected measurement range for miRNAs of interest when using

customized qPCR plates, and to compare the results from each batch of customized qPCR plates with individual qPCR assays.

We and others have noted difficulties comparing miRNA measurements from different technologies. In particular, there is poor agreement between microarrays and qPCRs when assessing quantitative changes. Microarray-based technologies use hybridization and are suitable for detecting the presence of miRNA species, but have limited quantitative accuracy and dynamic range. Similarly, NGS has several drawbacks, in particular requiring much larger sample volumes than qPCR analysis, and the introduction of amplification bias for certain miRNAs during library preparation. For example, in our study we obtained most reads for miR-486, a miRNA that is present in the circulation but has a relatively high Ct value by qPCR, suggesting it is much less abundant than other circulating miRNAs. Thus, miRNAs with more sequencing reads are not necessarily more abundant (**Figure 5**). Quantitative comparison must only be made by comparing sequencing reads for the same miRNAs.

Freedman et al used high-throughput microfluidic quantitative PCR to analyse the miRNA signature in blood (whole blood, platelets, mononuclear cells, plasma, and serum) collected from 5 healthy individuals. They screened for 852 miRNAs in 83 patients undergoing diagnostic coronary angiography and categorised their patients into two groups: with coronary artery stenosis  $\geq 70\%$  (n=34) and without (n=49). Increased plasma expression of miR-494, miR-769-3p and miR-490-3p was associated with  $\geq 70\%$  coronary stenosis and logistic regression analysis found anti-hypertensive therapy, smoking and miR-769-3p were significantly associated with coronary status.<sup>105</sup> The very low correlation of the most abundant platelet miRNAs found in this study is striking. Only one of the commonly reported highly expressed miRNAs (miR-92a) was detected. It is likely that there are similar discrepancies with plasma miRNA measurements. One cause for this difference may be the high-throughput BioMark Real-Time Fluidigm PCR system used in this study to increase the number of miRNA measurements that can be performed simultaneously, as no validation by conventional qPCR was provided.

### Potential for Clinical Translation

The miRNA biomarker field is currently nascent. While there is much to link the expression of miRNAs to various diseases, the clinical utility or validity of miRNA detection has not been demonstrated. Currently, miRNAs are manually extracted, presenting the largest obstacle to increasing throughput. If new technological platforms provide the opportunity for faster miRNA extraction or direct analysis of miRNAs without the need for miRNA extraction, they will significantly improve the “ease-of-use” in clinical settings. Increasing throughput, however, must not compromise the quantitative accuracy of the analysis for both low- and high-abundance miRNAs. Ideally, miRNA measurements need to be able to out-perform current diagnostic methods to reach the clinical mainstream.

In addition to current practical limitations, miRNA biomarkers will also need to be presented in the context of related miRNAs in order to be adequately interpreted. There are relatively few tissue-specific miRNAs, with miR-122 being an exception given its exquisite liver specificity.<sup>106</sup> We recently showed that high circulating miR-122 levels are associated with an adverse lipid profile, and predict development of metabolic syndrome and diabetes mellitus type 2.<sup>107</sup> However, most circulating miRNAs are ubiquitously expressed and numerous cell types can release miRNAs. This complicates its clinical application, as levels of individual miRNAs can greatly vary between patients, without any pathological significance. Therefore, it is crucial to represent relative expression levels of a miRNA in relation to a network of several other miRNAs. The use of a so-called “miRNA signature” can greatly strengthen the predictive and diagnostic value.



As the origin of many plasma miRNAs is unknown, De Rosa et al investigated trans-coronary gradients of various miRNA in patients with acute coronary syndrome in a bid to define coronary-specific changes in the setting of myocardial damage. Samples were taken from the aorta and coronary sinus. They found an upregulation of the muscle-enriched miR-499, -133a, and -208a in acute coronary syndrome patients, of which miR-499 correlated with troponin levels, an established clinical marker of myocardial damage. Contrary to their predictions, miR-126 decreased across the coronary circulation, despite its high expression in endothelial cells. They also described a negative trend for miR-223 across the coronary circulation in the acute coronary syndrome group but not in the stable coronary artery disease group; however this did not reach statistical significance.<sup>108</sup> An alternative explanation for the reduction in miR-126 and miR-223 across the coronary circulation is the retention of platelets and platelet MPs in the affected myocardium, or differential activation of platelets in venous and arterial settings.

Pharmacological inhibitors can be used to identify the cellular origins of miRNAs. By comparing plasma miRNA levels in the same individuals before and after initiation of anti-platelet therapy, we identified a set of plasma miRNAs that is responsive to anti-platelet therapy.<sup>32</sup> The miRNA candidates were abundant in platelets, but they were not platelet-specific. Moreover, not every abundant platelet miRNA was equally affected by anti-platelet medication. Some miRNAs, despite their abundance in platelets, may be expressed at higher levels in other cell types. Consequently, their plasma levels may be less dependent on platelets. Given the platelet origin of many abundant miRNAs, it is not surprising that the same miRNAs are deregulated in multiple diseases. The question, however, remains whether the circulating miRNA changes are cause or consequence. In cancer, for example, many of the miRNA alterations may be due to platelet activation, rather than the release of miRNAs from tumor tissue.

Early studies compared platelet samples from different individuals. Longitudinal sampling eliminates inter-individual variability. For example, using serial measurements before and after anti-platelet medication, we investigated the effect of 10mg prasugrel followed by the addition of an escalating aspirin dose regimen (75mg daily in week 2, 300mg daily in week 3) on the PPP miRNA signature of healthy young volunteers. Using custom made miRNA qPCR plates, 92 targets were measured at four different time points. Antiplatelet therapy was associated with a reduction in plasma miR-223, -126, -15, -191, -20b, -21, and -24. The findings were replicated in plasma of patients with recent symptomatic carotid atherosclerosis who had begun treatment with dipyridamole or clopidogrel, in addition to aspirin. These patients showed a reduction in miR-223, miR-126, miR-150, and miR-191.<sup>34</sup> The effect was less pronounced, presumably because the symptomatic patients were on aspirin medication at baseline and the follow-up measurement was only taken after 48 h. The reduction in platelet miRNAs upon platelet inhibition complements previous findings by Zampetaki et al in an ischemia/reperfusion injury model by thigh cuff inflation, in which plasma platelet miRNAs increased upon platelet activation.<sup>75</sup>

The clinical use of platelet function tests is limited at present, despite clear differences in response to pharmacological platelet inhibition. In the case of clopidogrel, a pro-drug, a large percentage of this variation can be attributed to different cytochrome P450 isoforms involved in its bioactivation.<sup>109</sup> However, this in itself does not explain all of the variation in efficacy. Measurements of platelet activity by light transmission aggregometry is considered the gold standard, but this test is performed *ex vivo* and not well standardized between laboratories. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation and VerifyNow P2Y<sub>12</sub> assays measure platelet activation in full blood but only in response to a single pathway, ADP stimulation. Platelet miRNAs may offer an opportunity to obtain an alternative read-out for platelet activation *in vivo* that integrates activation by multiple agonists rather than just ADP (**Figure 6**). Platelet miRNA measurements, however, will only be useful if they provide diagnostic advantages. They also must be easy to perform, and

capable of discriminating the degree of inter-individual variability in platelet inhibition or platelet turnover.

## Conclusions

Initially, circulating miRNAs were thought to originate from tissue injury. This is indeed the case for cardiac miRNAs that are released after myocardial infarction akin to troponins. For basal miRNA levels, however, the importance of circulating cells is now apparent, and the contribution from anucleate cells such as erythrocytes and platelets must not be underestimated. Several challenges face the accurate detection and use of plasma and serum miRNAs:

(1) Variability in samples' cell composition affects miRNA profiles. This includes anuclear cells such as erythrocytes and residual platelets. Pre-analytical variation in sample preparation or handling must be minimized to avoid alterations of results. Given the platelet origin of many abundant miRNAs in plasma and serum, the use of PPP would seem to be the most appropriate substrate for miRNA measurements. In conventional plasma samples, the number of residual platelets can vary. Also, without inhibitors, platelet activation may occur during centrifugation. In serum, the stability of miRNAs may be affected, and miRNAs may be trapped in the clot. This could introduce bias that affects results, in particular if the clotting time varies between sampling.

(2) The concentration of extracellularly circulating miRNAs is very low, and the miRNA yield of plasma and serum is insufficient for conventional quality control methods, such as optical densitometry or Bioanalyzer. Generally, equal volumes of plasma and serum are used for extraction. No correction is performed for RNA content. This approach of normalizing by volume is, however, analogous to protein measurements. In both cases, the total RNA or total protein amount of plasma would not be a suitable normalization control for the miRNA or protein biomarker of interest.

(3) Currently, there is no endogenous control for the normalization of circulating miRNAs. Instead, exogenous spike-in controls are used for normalizing the extraction procedure. The values of spike-in controls such as Cel-miR-39 relate entirely to the consistency of the isolation procedure, not to the starting RNA quantity. By measuring a broader panel of unrelated miRNAs, the mean Ct value can be used for normalization.

(4) MiRNAs in plasma and serum are highly correlated. Assessing individual miRNAs without integration into a wider miRNA network is of limited utility. Relative changes in miRNAs to one another (so-called "miRNA signatures") can be more informative than the changes of individual miRNAs.

These points will need to be addressed in future publications on miRNA biomarkers in order to facilitate comparability between studies, something that has been difficult with variations between measurement platforms and lack of guidelines for standardization. Standardized miRNA measurement platforms are currently under development, which could reduce measurement variability, whilst facilitating cross-study comparisons. In addition to the need for consensus on sample preparation and analytical procedures, future research will need to move on from reporting on single miRNAs and focus more on miRNA signatures. However, these issues are not insurmountable, and once addressed, future studies can further evaluate the potential of miRNA biomarkers for clinical use and whether miRNA assays will outperform existing clinical measurements.

### **Acknowledgement**

We thank Dr Raimund Pechlaner and Dr Peter Willeit from the Department of Neurology, Medical University of Innsbruck, Austria for providing figures.

### **Sources of Funding**

M.M. is a Senior fellow of the British Heart Foundation (BHF, FS/13/2/29892) and supported by the Fondation Leducq (MIRVAD; 13 CVD 02) and the NIHR Biomedical Research Center based at Guy's and St. Thomas' National Health Service Foundation Trust and King's College London, in partnership with King's College Hospital. T.B. is an Interdisciplinary Ph.D. student funded by the BHF. A.J. has been awarded a BHF Clinical Research Training Fellowship. R.P.H. and R.C.L. are supported by funding from a British Heart Foundation grant (RG/13/5/30112) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

### **Disclosures**

M.M. is named inventor on patents that detail claims related to circulating miRNAs as biomarkers. M.M. has received a research grant from Astra Zeneca for investigating the effects of anti-platelets on circulating miRNAs.

## References

1. Gurbel PA, Jeong YH, Navarese EP, Tantry US. Platelet-Mediated Thrombosis: From Bench to Bedside. *Circ Res*. 2016;118:1380-91.
2. Roth GJ, Hickey MJ, Chung DW, Hickstein DD. Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. *Biochem Biophys Res Commun*. 1989;160:705-10.
3. Warshaw AL, Laster L, Shulman NR. Protein synthesis by human platelets. *J Biol Chem*. 1967;242:2094-7.
4. Bray PF, McKenzie SE, Edelstein LC, Nagalla S, Delgrosso K, Ertel A, Kupper J, Jing Y, Londin E, Loher P, Chen HW, Fortina P, Rigoutsos I. The complex transcriptional landscape of the anucleate human platelet. *BMC Genomics*. 2013;14:1.
5. Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, Yost CC, Zimmerman GA, Weyrich AS. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. *Blood*. 2011;118:e101-11.
6. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. *Nat Struct Mol Biol*. 2009;16:961-6.
7. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. *Blood*. 2011;117:5189-97.
8. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A*. 2008;105:10513-8.
9. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A*. 2011;108:5003-8.
10. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol*. 2011;13:423-33.
11. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. *Nucleic Acids Res*. 2011;39:7223-33.
12. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB. Detection of microRNA expression in human peripheral blood microvesicles. *PLoS ONE*. 2008;3:e3694.
13. Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E, Klement GL, Sola-Visner M, Italiano JE, Jr. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. *Blood*. 2009;113:1112-21.
14. Burnouf T, Goubran HA, Chou ML, Devos D, Radosevic M. Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. *Blood Rev*. 2014;28:155-66.
15. Italiano JE, Jr., Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. *Curr Opin Hematol*. 2010;17:578-84.
16. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9:654-9.
17. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, Boilard E, Provost P. Activated platelets can deliver mRNA regulatory Ago2\*microRNA complexes to endothelial cells via microparticles. *Blood*. 2013;122:253-61.
18. McManus DD, Freedman JE. MicroRNAs in platelet function and cardiovascular disease. *Nat Rev Cardiol*. 2015;12:711-7.
19. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res*. 2014;42:D68-73.

20. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136:215-33.
21. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res*. 2009;19:92-105.
22. Selbach M, Schwanhaussner B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature*. 2008;455:58-63.
23. Barwari T, Joshi A, Mayr M. MicroRNAs in Cardiovascular Disease. *J Am Coll Cardiol*. 2016;68:2577-2584.
24. Ipsaro JJ, Joshua-Tor L. From guide to target: molecular insights into eukaryotic RNA-interference machinery. *Nat Struct Mol Biol*. 2015;22:20-8.
25. Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. *Nat Rev Genet*. 2015;16:421-33.
26. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. *Nature*. 2004;432:231-5.
27. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs. *Nature*. 2004;432:235-40.
28. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature*. 2005;436:740-4.
29. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. *Nat Rev Mol Cell Biol*. 2007;8:23-36.
30. Opalinska JB, Bersenev A, Zhang Z, Schmaier AA, Choi J, Yao Y, D'Souza J, Tong W, Weiss MJ. MicroRNA expression in maturing murine megakaryocytes. *Blood*. 2010;116:e128-38.
31. Creemers EE, Tijssen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circ Res*. 2012;110:483-95.
32. Kaudewitz D, Skroblin P, Bender LH, et al. Association of MicroRNAs and YRNAs With Platelet Function. *Circ Res*. 2016;118:420-32.
33. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. *Arterioscler Thromb Vasc Biol*. 2013;33:206-14.
34. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. *Circ Res*. 2013;112:595-600.
35. Bleazard T, Lamb JA, Griffiths-Jones S. Bias in microRNA functional enrichment analysis. *Bioinformatics*. 2015;31:1592-8.
36. Huntley RP, Sitnikov D, Orlic-Milacic M, et al. Guidelines for the functional annotation of microRNAs using the Gene Ontology. *RNA*. 2016;22:667-76.
37. Gene Ontology microRNAs. Available from: <https://www.ucl.ac.uk/functional-gene-annotation/cardiovascular/projects/tabs/gene-ontology-mirnas>. Accessed on: 23 Nov 2016.
38. AmiGO2 Kaudewitz et al. Available from: <http://amigo.geneontology.org/amigo/reference/PMID:26646931>. Accessed on: 23 Nov 2016.
39. Wolin SL, Steitz JA. Genes for two small cytoplasmic Ro RNAs are adjacent and appear to be single-copy in the human genome. *Cell*. 1983;32:735-44.
40. Perreault J, Perreault JP, Boire G. Ro-associated Y RNAs in metazoans: evolution and diversification. *Mol Biol Evol*. 2007;24:1678-89.
41. Christov CP, Gardiner TJ, Szuts D, Krude T. Functional requirement of noncoding Y RNAs for human chromosomal DNA replication. *Mol Cell Biol*. 2006;26:6993-7004.
42. Hogg JR, Collins K. Human Y5 RNA specializes a Ro ribonucleoprotein for 5S ribosomal RNA quality control. *Genes Dev*. 2007;21:3067-72.
43. Chen X, Wolin SL. The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity. *J Mol Med (Berl)*. 2004;82:232-9.

44. Dhahbi JM, Spindler SR, Atamna H, Boffelli D, Mote P, Martin DI. 5'-YRNA fragments derived by processing of transcripts from specific YRNA genes and pseudogenes are abundant in human serum and plasma. *Physiol Genomics*. 2013;45:990-8.
45. Nicolas FE, Hall AE, Csorba T, Turnbull C, Dalmay T. Biogenesis of Y RNA-derived small RNAs is independent of the microRNA pathway. *FEBS Lett*. 2012;586:1226-30.
46. Bottcher K, Wenzel A, Warnecke JM. Investigation of the origin of extracellular RNA in human cell culture. *Ann N Y Acad Sci*. 2006;1075:50-6.
47. Cabrera-Fuentes HA, Ruiz-Meana M, Simsekylmaz S, et al. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-alpha in cardiac ischaemia/reperfusion injury. *Thromb Haemost*. 2014;112:1110-9.
48. Zernecke A, Preissner KT. Extracellular Ribonucleic Acids (RNA) Enter the Stage in Cardiovascular Disease. *Circ Res*. 2016;118:469-79.
49. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res*. 2012;22:1775-89.
50. Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F, Thum T. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. *Circ Res*. 2014;114:1569-75.
51. Skroblin P, Mayr M. "Going long": long non-coding RNAs as biomarkers. *Circ Res*. 2014;115:607-9.
52. Alhasan AA, Izuogu OG, Al-Balool HH, Steyn JS, Evans A, Colzani M, Ghevaert C, Mountford JC, Marenah L, Elliott DJ, Santibanez-Koref M, Jackson MS. Circular RNA enrichment in platelets is a signature of transcriptome degradation. *Blood*. 2016;127:e1-e11.
53. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. *Proc Natl Acad Sci U S A*. 1976;73:3852-6.
54. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. *PLoS ONE*. 2012;7:e30733.
55. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature*. 2013;495:333-8.
56. Chen LL. The biogenesis and emerging roles of circular RNAs. *Nat Rev Mol Cell Biol*. 2016;17:205-11.
57. Conn SJ, Pillman KA, Toubia J, Conn VM, Salamanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. *Cell*. 2015;160:1125-34.
58. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. *Nature*. 2013;495:384-8.
59. Plé H, Maltais M, Corduan A, Rousseau G, Madore F, Provost P. Alteration of the platelet transcriptome in chronic kidney disease. *Thromb Haemost*. 2012;108:605-15.
60. Simon LM, Edelstein LC, Nagalla S, Woodley AB, Chen ES, Kong X, Ma L, Fortina P, Kunapuli S, Holinstat M, McKenzie SE, Dong JF, Shaw CA, Bray PF. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. *Blood*. 2014;123:e37-45.
61. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the MicroRNA spectrum between serum and plasma. *PLoS ONE*. 2012;7:e41561.
62. Yu S, Deng G, Qian D, Xie Z, Sun H, Huang D, Li Q. Detection of apoptosis-associated microRNA in human apheresis platelets during storage by quantitative real-time polymerase chain reaction analysis. *Blood Transfus*. 2014;12:541-7.
63. Ferreira JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. *Thromb Haemost*. 2010;103:1128-35.
64. Capodanno D, Patel A, Dharmashankar K, Ferreira JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA,

- Angiolillo DJ. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. *Circ Cardiovasc Interv.* 2011;4:180-7.
65. Bernlochner I, Goedel A, Plischke C, Schupke S, Haller B, Schulz C, Mayer K, Morath T, Braun S, Schunkert H, Siess W, Kastrati A, Laugwitz KL. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. *Eur Heart J.* 2015;36:3202-10.
  66. Stratz C, Nuhrenberg TG, Binder H, Valina CM, Trenk D, Hochholzer W, Neumann FJ, Fiebich BL. Micro-array profiling exhibits remarkable intra-individual stability of human platelet micro-RNA. *Thromb Haemost.* 2012;107:634-41.
  67. Gidlof O, van der Brug M, Ohman J, Gilje P, Olde B, Wahlestedt C, Erlinge D. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. *Blood.* 2013;121:3908-17, S1-26.
  68. Ward JA, Esa N, Pidikiti R, Freedman JE, Keaney JF, Tanriverdi K, Vitseva O, Ambros V, Lee R, McManus DD. Circulating Cell and Plasma microRNA Profiles Differ between Non-ST-Segment and ST-Segment-Elevation Myocardial Infarction. *Fam Med Med Sci Res.* 2013;2:108.
  69. Elgheznawy A, Shi L, Hu J, Wittig I, Laban H, Pircher J, Mann A, Provost P, Randriamboavonjy V, Fleming I. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. *Circ Res.* 2015;117:157-65.
  70. Liang H, Yan X, Pan Y, Wang Y, Wang N, Li L, Liu Y, Chen X, Zhang CY, Gu H, Zen K. MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. *Mol Cancer.* 2015;14:58.
  71. Risitano A, Beaulieu LM, Vitseva O, Freedman JE. Platelets and platelet-like particles mediate intercellular RNA transfer. *Blood.* 2012;119:6288-95.
  72. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res.* 2010;107:810-7.
  73. Randriamboavonjy V, Isaak J, Elgheznawy A, Pistrosch F, Fromel T, Yin X, Badenhop K, Heide H, Mayr M, Fleming I. Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. *Blood.* 2012;120:415-23.
  74. Zampetaki A, Mayr M. Sweet dicer: impairment of micro-RNA processing by diabetes. *Circ Res.* 2015;117:116-8.
  75. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. *J Am Coll Cardiol.* 2012;60:290-9.
  76. Schulte C, Molz S, Appelbaum S, Karakas M, Ojeda F, Lau DM, Hartmann T, Lackner KJ, Westermann D, Schnabel RB, Blankenberg S, Zeller T. miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients with Symptomatic Coronary Artery Disease. *PLoS ONE.* 2015;10:e0145930.
  77. Zampetaki A, Willeit P, Burr S, Yin X, Langley SR, Kiechl S, Klein R, Rossing P, Chaturvedi N, Mayr M. Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. *Diabetes.* 2016;65:216-27.
  78. Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW, Shaw C, Bray PF. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. *J Thromb Haemost.* 2010;8:369-78.
  79. Shi R, Ge L, Zhou X, Ji WJ, Lu RY, Zhang YY, Zeng S, Liu X, Zhao JH, Zhang WC, Jiang TM, Li YM. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. *Thromb Res.* 2013;131:508-13.
  80. Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, Dong JF, Shaw C, Bray PF. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. *Nat Med.* 2013;19:1609-16.

81. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. *J Thromb Haemost.* 2006;4:2317-26.
82. Chyrchel B, Toton-Zuranska J, Kruszelnicka O, Chyrchel M, Mielecki W, Kolton-Wroz M, Wolkow P, Surdacki A. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. *Platelets.* 2015;26:593-7.
83. Zhang YY, Zhou X, Ji WJ, Shi R, Lu RY, Li JL, Yang GH, Luo T, Zhang JQ, Zhao JH, Jiang TM, Li YM. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. *J Thromb Thrombolysis.* 2014;38:65-72.
84. Leierseder S, Petzold T, Zhang L, Loyer X, Massberg S, Engelhardt S. MiR-223 is dispensable for platelet production and function in mice. *Thromb Haemost.* 2013;110:1207-14.
85. Badrnya S, Baumgartner R, Assinger A. Smoking alters circulating plasma microvesicle pattern and microRNA signatures. *Thromb Haemost.* 2014;112:128-36.
86. Duan X, Zhan Q, Song B, Zeng S, Zhou J, Long Y, Lu J, Li Z, Yuan M, Chen X, Yang Q, Xia J. Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. *J Diabetes Complications.* 2014;28:705-10.
87. de Boer HC, van Solingen C, Prins J, Duijs JM, Huisman MV, Rabelink TJ, van Zonneveld AJ. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. *Eur Heart J.* 2013;34:3451-7.
88. Yu XY, Chen JY, Zheng ZW, Wu H, Li LW, Zhang ZW, Chen ZH, Lin QX, Han YL, Zhong SL. Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention. *EuroIntervention.* 2013;9:546-54.
89. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RT, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, Weber C. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. *Nat Med.* 2014;20:368-76.
90. Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, Schmitz T, Dolf A, Endl E, Franklin BS, Sinning JM, Vasa-Nicotera M, Nickenig G, Werner N. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. *J Am Heart Assoc.* 2014;3:e001249.
91. Pan Y, Liang H, Liu H, Li D, Chen X, Li L, Zhang CY, Zen K. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. *J Immunol.* 2014;192:437-46.
92. Prokopi M, Mayr M. Proteomics: a reality-check for putative stem cells. *Circ Res.* 2011;108:499-511.
93. Prokopi M, Pula G, Mayr U, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. *Blood.* 2009;114:723-32.
94. Sondermeijer BM, Bakker A, Halliani A, et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340\* and miRNA624\*. *PLoS ONE.* 2011;6:e25946.
95. Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC. Plasma processing conditions substantially influence circulating microRNA biomarker levels. *PLoS ONE.* 2013;8:e64795.
96. Mitchell AJ, Gray WD, Hayek SS, Ko YA, Thomas S, Rooney K, Awad M, Roback JD, Quyyumi A, Searles CD. Platelets confound the measurement of extracellular miRNA in archived plasma. *Sci Rep.* 2016;6:32651.
97. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. *Cancer Prev Res (Phila).* 2012;5:492-7.



98. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M, Dahlsveen IK. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. *Methods*. 2013;59:S1-6.
99. Kirschner MB, van Zandwijk N, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. *Front Genet*. 2013;4:56.
100. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. *Br J Cancer*. 2011;104:1168-77.
101. Benz F, Roderburg C, Vargas Cardenas D, Vucur M, Gautheron J, Koch A, Zimmermann H, Janssen J, Nieuwenhuijsen L, Luedde M, Frey N, Tacke F, Trautwein C, Luedde T. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. *Exp Mol Med*. 2013;45:e42.
102. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J. A novel and universal method for microRNA RT-qPCR data normalization. *Genome Biol*. 2009;10:R64.
103. Boeckel JN, Thome CE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S. Heparin selectively affects the quantification of microRNAs in human blood samples. *Clin Chem*. 2013;59:1125-7.
104. Kaudewitz D, Lee R, Willeit P, McGregor R, Markus HS, Kiechl S, Zampetaki A, Storey RF, Channon KM, Mayr M. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. *Thromb Haemost*. 2013;110:609-15.
105. Freedman JE, Ercan B, Morin KM, Liu CT, Tamer L, Ayaz L, Kanadasi M, Cicek D, Seyhan AI, Akilli RE, Camci C, Cengiz B, Oztuzcu S, Tanriverdi K. The distribution of circulating microRNA and their relation to coronary disease. *F1000Res*. 2012;1:50.
106. Willeit P, Skrobilin P, Kiechl S, Fernandez-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? *Eur Heart J*. 2016.
107. Willeit P, Skrobilin P, Moschen AR, et al. Circulating MicroRNA-122 Is Associated With The Risk of New-Onset Metabolic Syndrome And Type-2-Diabetes. *Diabetes*. 2016 (in press).
108. De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. *Circulation*. 2011;124:1936-44.
109. Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. *Eur Heart J*. 2009;30:1744-52.
110. Kato Y, Sato K, Asai K, Akutsu T. Rtips: fast and accurate tools for RNA 2D structure prediction using integer programming. *Nucleic Acids Res*. 2012;40:W29-34.
111. Osman A, Falker K. Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes. *Platelets*. 2011;22:433-41.

**Table 1. Minimum reporting standards and methodological recommendations for the analysis of circulating miRNAs.**

<b>Minimum reporting standards</b>	<b>Recommendations</b>
1. Phlebotomy protocol	Sample venous blood using butterfly or regular blood collection needle; standardize relevant pre-analytical variables (e.g. fasting, smoking, exercise)
2. Anticoagulant used	Use citrate or EDTA; avoid heparin due to interference with qPCR
3. Time until processing	Complete sample processing within 2 hours from sampling to minimize variability and degradation
4. Sample processing	Perform an initial soft spin to collect plasma, followed by a faster platelet depletion spin with added inhibitors of platelet activation.
5. Sample storage	Store samples at -80°C, avoiding freeze-thaw cycles prior to analysis.
6. RNA protocol	Use a validated miRNA or total RNA extraction kit; use a carrier (MS2 protein or glycogen); avoid potential batch effects by co-isolating RNA from across compared groups.
7. miRNA measurement platform	Avoid batch effects of different technical lots for used laboratory material and equipment
8. Average Ct levels for each assay	Assays with an average Ct value >32 (when using a 40-cycle protocol) should be avoided. Report average values to facilitate adequate interpretation of presented fold changes.
9. Variability of the normalization reference	Across-sample variability of quality control markers such as an exogenous spike-in miRNA should be no more than 1-2 PCR cycles
10. Normalization method(s)	Normalize to the average Ct value of multiple assays or to an exogenous spike-in control.

## Figure legends

**Figure 1. Overview of non-coding RNAs in platelets.** Although platelets are anucleate, they contain genetic material in the form of non-coding RNAs. These include small non-coding RNAs, such as microRNAs (miRNAs) and YRNA fragments as well as long non-coding RNAs, such as circular RNAs (circRNAs). Secondary structures of RNA sequences were predicted using RTips.

**Figure 2. Small non-coding RNAs in plasma.** A) Two peaks corresponding to miRNAs and YRNAs were observed by small RNA sequencing in plasma. B) Correlation of YRNA fragments to plasma levels of platelet factor 4 (PF4), pro-platelet basic protein (PPBP), and P-selectin (SELP). Lipocalin 2 (LCN2) was used as control. N=667.

**Figure 3. Platelet miRNA levels.** Relative abundance of miRNAs in platelets were reported in 8 studies (indicated by first author). The 50 highest ranking on average are presented here, indicating marked variation between different studies for the miRNAs beyond the top-10.

**Figure 4. Choice of samples.** A) Workflow for the preparation of PPP from PRP. Addition of prostacyclin inhibits platelet activation during centrifugation. B) Concerns with regards to miRNA measurements in the different samples range from a contamination with leukocytes in PRP, proteolytic activity in serum to residual platelets in plasma. PRP and serum should reflect platelet miRNA content; PPP platelet miRNA release; plasma samples will reflect extracellular miRNA content but may additionally reflect either, platelet miRNA content or release. This depends on the amount of residual platelets in the plasma samples or platelet activation during plasma preparation, in particular during centrifugation.

**Figure 5. Discrepancy between miRNA quantitation by RT-qPCR and RNA sequencing.** Average expression of 92 miRNAs was assessed in platelet-poor plasma from healthy subjects (n=12), using custom-made Exiqon LNA qPCR plates. Cycle-to-threshold (Ct) values are shown as 40-Ct (x-axis). Small RNA sequencing was performed with platelet-poor plasma from healthy subjects (n=2). miR-486-5p is highlighted, showing high sequencing reads (y-axis) despite inferred mid-range abundance by qPCR.

**Figure 6. MiRNAs and platelet reactivity.** Association of miR-126 and miR-223 levels in PPP to the Verify Now P2Y12 aggregation test (A) and the VASP phosphorylation assay (B) in patients on dual anti-platelet therapy for 30 days post acute coronary syndrome. Note that fewer samples were measured with the Verify Now (n=39) compared to the VASP assay (n=123). PRU, denotes P2Y12 Reaction Units (x-axis). Higher PRU values reflect higher P2Y12-mediated platelet reactivity.